An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

Bei Wang; Jin He; Chen Liu; Lung Ji Chang

doi:10.1016/j.vaccine.2006.02.025

An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

Bei Wang, Jin He, Chen Liu, Lung Ji Chang

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Viral modification of dendritic cells (DCs) may deliver a "danger signal" critical to the hypo-reactive DCs in cancer patients. Using three highly differentially expressed hepatoma tumor-associated antigens (TAAs): stem cell antigen-2 (Sca-2), glycoprotein 38 (GP38) and cellular retinoic acid binding protein 1 (RABP1), we explored the therapeutic potential of the DCs modified with lentiviral vectors (LVs). Preventive and therapeutic injection of the LV-TAA-DC vaccine into tumor-bearing mice elicited a strong anti-tumor response and extended survival, which was associated with tumor-specific interferon-γ and cytotoxic T cell responses. In vivo elimination of the LV-TAA-DCs by a co-expressed thymidine kinase suicide gene abrogated the therapeutic effect. The modification of DCs with LVs encoding multiple TAAs offers a great opportunity in cancer immunotherapy.

Original language	English (US)
Pages (from-to)	3477-3489
Number of pages	13
Journal	Vaccine
Volume	24
Issue number	17
DOIs	https://doi.org/10.1016/j.vaccine.2006.02.025
State	Published - Apr 24 2006
Externally published	Yes

All Science Journal Classification (ASJC) codes

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Keywords

Dendritic cells
Hepatoma
Lentiviral vectors
Tumor-associated antigen

Access to Document

10.1016/j.vaccine.2006.02.025

Cite this

@article{a704b8ef981040b28e5574ce467b3887,

title = "An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens",

abstract = "Viral modification of dendritic cells (DCs) may deliver a {"}danger signal{"} critical to the hypo-reactive DCs in cancer patients. Using three highly differentially expressed hepatoma tumor-associated antigens (TAAs): stem cell antigen-2 (Sca-2), glycoprotein 38 (GP38) and cellular retinoic acid binding protein 1 (RABP1), we explored the therapeutic potential of the DCs modified with lentiviral vectors (LVs). Preventive and therapeutic injection of the LV-TAA-DC vaccine into tumor-bearing mice elicited a strong anti-tumor response and extended survival, which was associated with tumor-specific interferon-γ and cytotoxic T cell responses. In vivo elimination of the LV-TAA-DCs by a co-expressed thymidine kinase suicide gene abrogated the therapeutic effect. The modification of DCs with LVs encoding multiple TAAs offers a great opportunity in cancer immunotherapy.",

keywords = "Dendritic cells, Hepatoma, Lentiviral vectors, Tumor-associated antigen",

author = "Bei Wang and Jin He and Chen Liu and Chang, {Lung Ji}",

note = "Funding Information: We thank X. Chen and W. Chou for technical assistance and G. Eubanks for editorial assistance with the manuscript. Part of the study had been presented in 2005 Keystone meeting and European Society of Gene Therapy meeting. This work was supported by NIH grant HL59412. L.J. Chang is a consultant to Innova Science PTE with financial interest to the lentiviral vector system used in this study.",

year = "2006",

month = apr,

day = "24",

doi = "10.1016/j.vaccine.2006.02.025",

language = "English (US)",

volume = "24",

pages = "3477--3489",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "17",

}

TY - JOUR

T1 - An effective cancer vaccine modality

T2 - Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

AU - Wang, Bei

AU - He, Jin

AU - Liu, Chen

AU - Chang, Lung Ji

N1 - Funding Information: We thank X. Chen and W. Chou for technical assistance and G. Eubanks for editorial assistance with the manuscript. Part of the study had been presented in 2005 Keystone meeting and European Society of Gene Therapy meeting. This work was supported by NIH grant HL59412. L.J. Chang is a consultant to Innova Science PTE with financial interest to the lentiviral vector system used in this study.

PY - 2006/4/24

Y1 - 2006/4/24

N2 - Viral modification of dendritic cells (DCs) may deliver a "danger signal" critical to the hypo-reactive DCs in cancer patients. Using three highly differentially expressed hepatoma tumor-associated antigens (TAAs): stem cell antigen-2 (Sca-2), glycoprotein 38 (GP38) and cellular retinoic acid binding protein 1 (RABP1), we explored the therapeutic potential of the DCs modified with lentiviral vectors (LVs). Preventive and therapeutic injection of the LV-TAA-DC vaccine into tumor-bearing mice elicited a strong anti-tumor response and extended survival, which was associated with tumor-specific interferon-γ and cytotoxic T cell responses. In vivo elimination of the LV-TAA-DCs by a co-expressed thymidine kinase suicide gene abrogated the therapeutic effect. The modification of DCs with LVs encoding multiple TAAs offers a great opportunity in cancer immunotherapy.

AB - Viral modification of dendritic cells (DCs) may deliver a "danger signal" critical to the hypo-reactive DCs in cancer patients. Using three highly differentially expressed hepatoma tumor-associated antigens (TAAs): stem cell antigen-2 (Sca-2), glycoprotein 38 (GP38) and cellular retinoic acid binding protein 1 (RABP1), we explored the therapeutic potential of the DCs modified with lentiviral vectors (LVs). Preventive and therapeutic injection of the LV-TAA-DC vaccine into tumor-bearing mice elicited a strong anti-tumor response and extended survival, which was associated with tumor-specific interferon-γ and cytotoxic T cell responses. In vivo elimination of the LV-TAA-DCs by a co-expressed thymidine kinase suicide gene abrogated the therapeutic effect. The modification of DCs with LVs encoding multiple TAAs offers a great opportunity in cancer immunotherapy.

KW - Dendritic cells

KW - Hepatoma

KW - Lentiviral vectors

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=33645229133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645229133&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.02.025

DO - 10.1016/j.vaccine.2006.02.025

M3 - Article

C2 - 16530303

AN - SCOPUS:33645229133

SN - 0264-410X

VL - 24

SP - 3477

EP - 3489

JO - Vaccine

JF - Vaccine

IS - 17

ER -

An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this